↓ Skip to main content

Dove Medical Press

Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma

Overview of attention for article published in OncoTargets and therapy, November 2016
Altmetric Badge

Mentioned by

twitter
2 X users

Readers on

mendeley
11 Mendeley
Title
Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma
Published in
OncoTargets and therapy, November 2016
DOI 10.2147/ott.s115668
Pubmed ID
Authors

Qing-Xuan Wang, En-Dong Chen, Ye-Feng Cai, Yi-Li Zhou, Zhou-Ci Zheng, Ying-Hao Wang, Yi-Xiang Jin, Wen-Xu Jin, Xiao-Hua Zhang, Ou-Chen Wang

Abstract

Thyroid cancer is the most frequent malignancies of the endocrine system, and it has became the fastest growing type of cancer worldwide. Much still remains unknown about the molecular mechanisms of thyroid cancer. Studies have found that some certain relationship between ARAP3 and human cancer. However, the role of ARAP3 in thyroid cancer has not been well explained. This study aimed to investigate the role of ARAP3 gene in papillary thyroid carcinoma. Whole exon sequence and whole genome sequence of primary papillary thyroid carcinoma (PTC) samples and matched adjacent normal thyroid tissue samples were performed and then bioinformatics analysis was carried out. PTC cell lines (TPC1, BCPAP, and KTC-1) with transfection of small interfering RNA were used to investigate the functions of ARAP3 gene, including cell proliferation assay, colony formation assay, migration assay, and invasion assay. Using next-generation sequence and bioinformatics analysis, we found ARAP3 genes may play an important role in thyroid cancer. Downregulation of ARAP3 significantly suppressed PTC cell lines (TPC1, BCPAP, and KTC-1), cell proliferation, colony formation, migration, and invasion. This study indicated that ARAP3 genes have important biological implications and may act as a potentially drugable target in PTC.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 2 18%
Student > Master 2 18%
Researcher 2 18%
Student > Ph. D. Student 1 9%
Professor 1 9%
Other 1 9%
Unknown 2 18%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 27%
Medicine and Dentistry 2 18%
Nursing and Health Professions 1 9%
Computer Science 1 9%
Agricultural and Biological Sciences 1 9%
Other 0 0%
Unknown 3 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2016.
All research outputs
#19,944,994
of 25,374,647 outputs
Outputs from OncoTargets and therapy
#1,447
of 3,016 outputs
Outputs of similar age
#231,759
of 317,808 outputs
Outputs of similar age from OncoTargets and therapy
#56
of 74 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,808 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 74 others from the same source and published within six weeks on either side of this one. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.